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ABSTRACT
Objective: To identify and critically assess previous
economic evaluations of smoking cessation
interventions delivered during pregnancy.
Design: Qualitative review of studies with primary data
collection or hypothetical modelling. Quality assessed
using the Quality of Health Economic Studies checklist.
Data sources: Electronic search of 13 databases
including Medline, Econlit, Embase, and PubMed, and
manual search of the UK’s National Institute of Health
and Care Excellence guidelines and US Surgeon
General.
Eligibility criteria for selecting studies: All study
designs considered if they were published in English,
evaluated a cessation intervention delivered to
pregnant women during pregnancy, and reported any
relevant economic evaluation metric (eg, cost per
quitter, incremental cost per quality adjusted life
year).
Results: 18 studies were included. 18 evaluations
were conducted alongside clinical trials, four were
part of observational studies, five were hypothetical
decision-analytic models and one combined
modelling with within-trial analysis. Analyses
conducted were cost-offset (nine studies), cost-
effectiveness (five studies), cost-utility (two studies),
and combined cost-effectiveness and cost-utility (two
studies). Six studies each were identified as high, fair
and poor quality, respectively. All interventions were
demonstrated to be cost-effective except motivational
interviewing which was dominated by usual care
(one study). Areas where the current literature was
limited were the robust investigation of uncertainty,
including time horizons that included outcomes
beyond the end of pregnancy, including major
morbidities for the mother and her infant, and
incorporating better estimates of postpartum relapse.
Conclusions: There are relatively few high quality
economic evaluations of cessation interventions
during pregnancy. The majority of the literature
suggests that such interventions offer value for
money; however, there are methodological issues
that require addressing, including investigating
uncertainty more robustly, utilising better estimates
for postpartum relapse, extending beyond a within-
pregnancy time horizon, and including major
morbidities for the mother and her infant for within-
pregnancy and beyond.
INTRODUCTION
A major global public health issue continues
to be tobacco smoking during pregnancy, with
a per annum economic burden conservatively
estimated to be £23.5 million in the UK,1 and
US$110 million in the USA.2 Not only is the
mother exposed to the long-term risks of
smoking,3 but has an increased risk of certain
pregnancy complications (eg, placenta abrup-
tion, ectopic pregnancy),4 while also having
serious consequences on her offspring.5–7 The
prevalence of smoking during pregnancy
among countries is highly varied, with approxi-
mately 39% in Spain,8 23% in Canada,9 to 12–
14% in the UK, US, Australia and
Germany.10–13 Suggested explanations for the
variation in prevalence are that countries with
the higher prevalence also had a greater pro-
portion of mothers with low-household
income, low-education levels and low-health lit-
eracy levels.14 15
Strengths and limitations of this study
▪ The review implies a broad search strategy of
13 electronic databases, so is likely to have
captured most, if not all, of the published
literature.
▪ A quality checklist has been used to systematic-
ally identify omissions and limitations of the
current literature, and has allowed a qualitative
synthesis to allow comparison between interven-
tions in common terms.
▪ The quality assessment could be considered as
subjective, and therefore is possibly influenced
by reviewer bias.
▪ Unpublished trials with published protocols were
included, however, other unpublished work was
not identified and therefore some relevant eva-
luations could have been omitted.
▪ The quality assessment tool is a good judge of
studies internal validity but cannot measure
external validity, and therefore the tool cannot
evaluate the generalisability of the results of
included studies.
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Economic evaluation is an important tool for deter-
mining which interventions deliver value for money and
is an integral part of the decision-making process for
new healthcare technologies. However, using the results
from poor quality evaluations are likely to lead to misin-
formed decisions being made and these could have sig-
niﬁcant negative impacts on health. While economic
evaluations of smoking cessation interventions in the
non-pregnant population have demonstrated that cessa-
tion is cost-effective (offer value for money in terms of
effectiveness in relation to cost),16 it would appear that
similar evidence for within-pregnancy cessation interven-
tions is sparse. A previous review published in 2008 iden-
tiﬁed only eight studies which involved economic
evaluations of cessation interventions delivered to preg-
nant smokers,17 and suggested that such interventions
could be considered potentially cost-effective. However,
a number of major studies have since been published, so
this review could now be considered out of date. The
primary aim of this paper was to identify and critically
assess economic evaluations of smoking cessation inter-
ventions delivered during pregnancy. The secondary
aims of this review were to identify any omissions and
limitations within previous evaluations, and to deter-
mine, which, if any, cessation interventions appeared to
be cost-effective.
METHODOLOGY
A previous review conducted by Ruger and Emmons17
has already been done on this topic; however, this review
could be considered to be out of date as the search was
last performed up to July 2003. Furthermore, this review
only searched two electronic databases (PubMed and
National Health Service Economic Evaluation Database
(NHS EED)), and therefore the authors felt that the
previous review’s search may have missed relevant arti-
cles. Therefore, the authors concluded to expand the
electronic search and search terms to ensure that a
maximum sensitivity search was conducted and that all
the relevant literature had been identiﬁed.
Database selection
Thirteen databases were searched: ASSIA, CINAHL,
Econlit, Embase, Maternity and Infant Care, Medline,
NHS EED, PsycArticles, PsycINFO, PubMed, Tufts
Cost-Effectiveness Analysis Registry, Web of Knowledge,
and Web of Science. Additionally, the websites of two
governmental health guidance bodies, the UK’s National
Institute for Health and Care Excellence (NICE) and
the US Surgeon General, were searched to identify any
evaluations published here as part of guideline develop-
ment.18 19 Databases were searched from inception
through to August 2014.
Search terms
The search strategy was developed using terms from a
previous review and the Cochrane Pregnancy and
Childbirth Group.17 20 Search terms and an example
search can be found in online supplementary ﬁle 1. For
the searches of the NICE and US Surgeon General web-
sites, the terms smoking, smoking cessation and preg-
nancy were used.
Inclusion criteria
Studies were included if they were in English, reported a
formal economic evaluation, with a direct comparison
between costs and outcomes, for example, ‘cost per
quitter’.
Population: Women who had experienced a cessation
intervention during pregnancy, and/or their infants/
children whose mother had been exposed to a cessation
intervention during pregnancy, or hypothetical cohorts
modelling cessation during pregnancy and/or after this.
Interventions: Any interventions or combination of
interventions, both real and hypothetical (an interven-
tion with an assumed quit rate), aimed at encouraging
pregnant smokers to quit.
Comparators: Any comparator intervention including
no intervention and ‘usual care’ (UC).
Outcomes: Clinical or economic outcomes considered
relevant to the mother and/or child (eg, smoking status
at end of pregnancy, low birth weight (LBW) (birth
weight <2500 g) births averted, sudden infant deaths
(SIDs) averted, and quality adjusted life years (QALYs)).
Design: Any type (see table 1 for brief deﬁnitions) and
design (including within-trial analyses21 and decision
Table 1 Brief definition of the different types of economic
evaluation
Type of economic
evaluation Definition
Cost-minimisation
(CMA)
Interventions are assumed to
have equal effectiveness and
are ranked in terms of cost (low
to high)
Cost-effectiveness
(CEA)
Effectiveness of interventions
are measured in their natural
scale (eg, number of quitters)
Cost-utility (CUA) Effectiveness of interventions
are measured using a generic
outcome which embodies health
related quality of life which
captures a patient’s preference
(utility) for a particular health
state/disease
Cost-benefit (CBA) Effectiveness of interventions
are measured in monetary units
Cost-consequence
(CCA)
Costs and consequences of an
intervention are reported
separately
Cost-offset(COA) Effectiveness of interventions is
measured in healthcare cost
savings generated by the
intervention
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analytic models (mathematical techniques to synthesise
information from multiple sources)22) of economic
evaluation were considered.
Exclusion criteria
Exclusion criteria were:
▸ Studies with no economic analyses
▸ Studies which focused on the delivery of a smoking
service and did not report an outcome that demon-
strated the effectiveness of an intervention in terms
of health beneﬁts to the mother/infant or reduction
in the number of women smoking by the end of preg-
nancy; examples of irrelevant outcomes include
number of general practitioners delivering a cessation
intervention, number of women accessing a cessation
intervention.
Identification of papers and data extraction
The lead reviewer screened titles and abstracts of
retrieved citations and potentially-relevant texts were
retrieved. If a protocol for an ongoing trial was identi-
ﬁed, the trial’s Principal Investigator was asked to
provide economic analysis details. Two reviewers working
independently assessed full texts for inclusion, extracted
data and applied a quality assessment checklist. If the
two reviewers disagreed on data extraction or quality
assessment, a third was consulted. A manual search was
conducted of references from included studies for other
potentially-relevant studies. Papers were then identically
screened and reviewed. Data extracted from each study
are given in table 2.
Quality assessment
To assess the methodology quality of included studies,
the Quality of Health Economic Studies (QHES) check-
list was chosen.23 The QHES has been demonstrated to
be a reliable and valid instrument,24–26 and was there-
fore chosen over other checklists because of its ease of
application and the quantitative aspect which would
allow comparison across the studies. The QHES contains
16 ‘yes/no’ response questions focusing on the both the
methodology of economic evaluations and the broader
study, with each question carrying a weighted point
score, out of a maximum of 100. The QHES instrument
can be found in online supplementary ﬁle 2.
When interpreting QHES questions, points were only
awarded if the reviewers believed that the most import-
ant criteria for the questions were met; if this was the
case all points would be awarded. The reviewers did not
award fewer points if the study only met some of the
question’s criteria, the response to each question either
being a ‘yes’ (therefore full points) or a ‘no’ (no
points). For three individual questions on the QHES
(questions ﬁve, eight, and 10), the authors speciﬁed
further criteria to be met in addition to those included
within the QHES question. Details of these additional
criteria can be found alongside the QHES instrument in
online supplementary ﬁle 2. Although there is no
established, standardised interpretation of the QHES
score, the following grouping was adopted based on the
work by Spiegel et al:27 0–24, extremely poor quality; 25–
49, poor quality; 50–74; fair quality; 75–100 high quality.
Data synthesis
No meta-analysis was speciﬁed prior to searches because
it was uncertain how studies could be combined;
however, the intention was to investigate whether or not
this approach would be possible after considering
included studies. It was anticipated that the review
would adopt a qualitative synthesis, but that a
meta-analysis on a subset of data would be investigated if
there was potential. The primary objective of the qualita-
tive synthesis would be to discuss the quality of the
methods used in identiﬁed studies, as determined by the
QHES. The results of the assessment from the QHES
would be used to demonstrate the strengths and weak-
nesses of each individual study and of the literature as a
whole. To facilitate this QHES scores were allocated to
studies as an indicator of overall study quality and quali-
tatively inspected the components of studies’ scores to
investigate which aspects of evaluation quality were com-
monly absent or poor across studies.
The secondary objectives of the qualitative synthesis
were to determine any omissions and limitations of pre-
vious evaluations, and to investigate what evidence there
was of the cost-effectiveness of within-pregnancy cessa-
tion interventions. To allow comparison between the
Table 2 Data extracted from studies
Area of topic Data extracted
General study
background
Author(s)
Publication year
Years of study
Study question
Funding source
Study design Study type and design
Description of intervention
Description of comparator
Outcomes measured
Study assumptions
Evaluation
characteristics
Setting (alongside trial vs
hypothetical modelling)
Type of economic evaluation
Modelling assumptions
Characteristics of resource
estimates (staff time, intervention
requirements, hospital use)
Characteristics of cost estimates
(staff cost, itemised costs, total
intervention and comparator costs,
incremental cost)
Discounting
Sensitivity analyses
Study results Results of evaluation
Comparison with other evaluations
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various evaluations, we grouped studies into those who
included primary data collection (eg, randomised con-
trolled trials (RCTs)) and those who utilised secondary
sources (eg, hypothetical decision analytic models). We
adopted this approach as we anticipated that there
would be very different assumptions made within the
studies, with RCTs likely to be focusing on a short time
horizon while decision analytic models a much longer
one. Furthermore, decision analytic models often
assume background quit rates or intervention/compara-
tor costs which may not be comparable with those col-
lected directly from an RCT.
RESULTS
The electronic search (conducted 7 August 2014) identi-
ﬁed 8954 citations, while the manual searches of the UK’s
National Institute of Health and Care Excellence (NICE)
and US Surgeon General’s websites returned a further 30
and zero studies, respectively. Screening identiﬁed 23
potential studies, four of which were ongoing randomised
control trials (RCTs) with published protocols.28–31
Contact with the trials’ Principal Investigators returned the
data for three RCTs,32–35 while for one, data were unavail-
able.30 Four studies were excluded during data extraction.
Two were conference abstracts which reported insufﬁcient
detail, and attempts to contact the authors failed.36 37 One
included no outcomes related to either cessation or preg-
nancy,38 and another did not test a cessation interven-
tion.39 The study PRISMA diagram can be found in
ﬁgure 1. Fifteen studies were published in peer reviewed
journals,32 35 40–52 two with NICE guidance53 54 and one
was a unpublished RCTs.33 As anticipated, it was decided
that a meta-analysis was inappropriate due to the
extremely heterogeneous nature of included studies.
Characteristics of studies
Key characteristics of included studies can be found in
online supplementary ﬁles 3 and 4. Five studies were
conducted in the UK,32 33 35 53 54 and the remainder in
the USA. There was wide variety in cessation interven-
tions, including: counselling-based (ﬁve studies)40–42 46 50;
self-help materials (two studies);43 51 combined self-help
materials and counselling (two studies);48 52 nicotine
replacement therapy (NRT) (one study);32 ﬁnancial
incentives (one study)35; and physical activity (one
study).33 Two studies investigated interventions that had
previously been described in the literature,53 54 while
four studies modelled hypothetical interventions.44 45 47 49
Comparator interventions among studies with primary
data collection were self-help materials (four
studies);41 43 48 52 brief advice (four studies);41 48 51 52
and standard UK National Health Service treatment
(see online supplementary ﬁle 3 for details) (two
studies).33 35 The following were used by one study each,
placebo patches with behavioural support;32 no
intervention;46 and a cessation programme that was not
deﬁned.42 For studies without primary data collection,
seven used an assumed or spontaneous background quit
rate,40 44 45 49 50 53 55 while one study used multiple com-
parators which included low intensity behavioural
support, non-conditional incentives and usual care (not
deﬁned).54
Cost-offset evaluations were used in nine studies,40
42–45 47 49 50 52 cost-effectiveness in ﬁve,32 33 41 46 51
cost-utility in two53 54 and two studies used cost-utility
and cost-effectiveness.35 48 Eight evaluations were con-
ducted within clinical trials,32 33 41–43 48 51 52 four were
part of observational studies,40 46 47 50 ﬁve were decision
analytic models,44 45 49 53 54 and one combined a within-
trial analysis with a decision analytic model.35 Twelve
studies used a healthcare provider perspective (focusing
on costs and outcomes directly related to the healthcare
provider), while six studies reported a societal perspec-
tive (including costs and outcomes directly and indir-
ectly related to the healthcare provider, patient and
society as a whole).32 33 35 48 53 54
Most evaluations adopted a short time horizon, with
12 studies considering only outcomes during pregnancy
or immediately afterwards.32 33 40–44 46 47 49–51 Only six
studies reported considering outcomes over the
mother’s lifetime,35 45 48 52–54 and two studies incorpo-
rated outcomes over the infant’s lifetime too.53 54 Cost
data were predominantly obtained from micro-costing
analyses (costing individual component parts separately
to generate a total cost for the intervention) collected
within clinical trials, with other cost estimates taken from
literature sources. Six studies reported discount rates (a
rate representing how much individuals discount future
health and cost), with rates of 3%,48 3.5%,35 53 54 4%45
and 5%.47
Measures of smoking cessation were the most frequent
primary outcomes (12 studies), while two studies used
the number of infants born with LBW (birth weight
<2500 g) prevented,44 45 one used SIDS (unexplained
death within the ﬁrst year of life) prevented,47 and three
used QALYs (a life year weighted by the patient’s prefer-
ence for being in a particular health state).48 53 54
Secondary outcomes were: LBW infants (six
studies),32 42 43 48 49 52 premature birth (two studies)
(birth occurring before 37 weeks gestation),43 49 pre-
natal death (three studies) (stillbirths and deaths in the
ﬁrst week of life),32 45 53 life years (two studies),48 55 and
QALYs (one study).35 When smoking status was used as
an outcome in trials, this was biochemically validated in
eight studies.32 33 35 40 46 48 51 52 Among studies using
QALYs, for mothers, one study awarded QALY gains
using previously published estimates of QALY gains for
quitters,48 a second study awarded QALYs on the basis of
the mothers smoking behaviour during and after preg-
nancy,35 while a two studies calculated QALYs for the
mother taking into account whether the mother smoked
postpregnancy and suffered from coronary heart
disease, chronic obstructive pulmonary disorder, myocar-
dial infarction, lung cancer or stroke.53 54 In addition,
one decision analytic model also included QALY losses
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associated ectopic pregnancy, spontaneous abortion and
pre-eclampsia.54 For studies including infants, one study
used previously published QALY estimates adjusting for
the higher mortality rate among children born to
smoking women,53 while a second awarded QALY losses
for birth weight below 2500 g, otitis media and asthma.54
Deterministic sensitivity analyses were used to investi-
gate the impact of assumptions made within the study
on the results of the economic evaluation in 10
studies;35 40 44–46 48 49 51–53 the most frequently varied
parameters were intervention effectiveness between high
and low quit rates,40 44 45 48 49 52 intervention cost
between high and low cost,40 45 46 48 51–53 and back-
ground quit rate between high and low rates.44 49 Four
studies used robust statistical techniques in probabilistic
sensitivity analyses.32 33 35 54
QHES assessment
Table 3 summarises QHES assessment results. Six studies
attained a score greater than 75 indicating high
quality,32 33 35 48 49 54 six were deemed of fair quality,41–45 53
and six poor.40 46 47 50–52 The median score was 58, with a
range from 33 to 87, and an inter-quartile range of 38.
Areas where studies seemed to perform poorly were: per-
forming a robust analysis of uncertainty (Q5, four studies),
inclusion of all major short-term and long-term maternal
and fetal outcomes (Q10, no studies), and incorporation
of a time horizon that included the effects within-
pregnancy and lifetime for the mother and infant (Q8,
one study).
Findings of studies with primary data collection
Ten studies reported the primary collection of cost
and effectiveness data,32 33 35 41–43 46 48 51 52 with all
except one study identiﬁed cessation interventions
during pregnancy as being cost-effective.48 One UK
randomised controlled trial (RCT) reported that the
intervention was dominant over usual care (domin-
ance occurs when one intervention costs less and is
more effective than another).33 Other UK RCTs found
the incremental cost per additional quitter was £4926
for NRT,32 and £1127 for ﬁnancial incentives.35 One
RCT extended the within-trial results to lifetime
horizon for the mother using a previously developed
model,56 and estimated an incremental cost per add-
itional QALY of £482 for ﬁnancial incentives.35 The
impact of uncertainty was explored in all three UK
RCTs. For NRT, the majority of the bootstrapping
iterations laid within the north east quadrant, suggest-
ing that NRT was likely to be more effective but more
costly than the comparator intervention consisting of
placebo patches and behavioural support.32 The prob-
ability of ﬁnancial incentives being cost-effective com-
pared to usual care at £20 000–£30 000 per QALY was
70%,34 while for physical activity the probability was
approximately 75%.33
Figure 1 Review PRISMA
diagram. RCTs, randomised
controlled trials.
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Table 3 Results of the QHES assessment
Author Year Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Total
Ayadi 2006 X X X X X 35
Cooper 2014 X X X X X X X X X X X X X X 87
Dornelas 2006 X X X X X X X X X X 67
Ershoff 1983 X X X X X X X X X 59
Ershoff 1990 X X X X X X X X X X X 71
Hueston 1994 X X X X X X X X X 57
Mallender 2013 X X X X X X X X X X X X 86
Marks 1990 X X X X X X X X 57
Parker 2007 X X X X X X 33
Pollack 2001 X X X X X X 36
Ruger 2008 X X X X X X X X X X X X X 78
Shipp 1992 X X X X X X X X X X X X 77
Tappin 2015 X X X X X X X X X X X X X X 87
Taylor 2009 X X X X X X X X 56
Thorsen 2004 X X X X X X 37
Ussher 2015 X X X X X X X X X X X X X X 87
Windsor 1988 X X X X X 35
Windsor 1993 X X X X X X X 49
Frequency 17 8 10 4 4 11 16 1 16 0 16 14 11 11 17 13
Percentage 94% 44% 56% 22% 22% 61% 89% 6% 89% 0% 89% 78% 61% 61% 94% 72%
X=yes on QHES.
QHES, Quality of Health Economic Studies.
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Among US studies, one RCT reported that using a
counselling intervention provided no additional beneﬁt
in QALYs and was therefore dominated by usual care.48
However, other studies found cost-beneﬁt ratios esti-
mated from 2:142 for self-help materials to 2.8:143 for
counselling, though one study found the cost-beneﬁt
ratio to be between US$1:17.93 to US$1:45.83 for com-
bined self-help materials and counselling.52 Another
study found an effectiveness to cost ratio of US$1:84.46
The incremental cost per quitter was reported as US
$298.76 for a counselling intervention41; while one study
found that for two different self-help material interven-
tions the incremental cost per quitter was US$50.93 and
US$118.83.51
To allow comparison between these studies, the incre-
mental cost was inﬂated to 2014 UK pound sterling
prices. UK costs were inﬂated using the Hospital &
Community Health Services Pay and Prices Index,57
while US costs were inﬂated to 2014 prices using the
Department of Labor’s Consumer Price Index
Calculator,58 and converted to UK pound sterling using
the exchange rate of US$1=GBP0.677173 (correct as of
April 2015). In addition to the incremental cost per add-
itional quitter, an incremental cost per additional quality
adjusted life year (QALY) was calculated. This was done
by assuming a QALY gain of 1.94 which was chosen from
previous work, based on the mean age of mothers across
the included studies ranging from 24 to 28 years.59 60
The results of this analysis can be found in table 4.
Findings from other included studies
Eight studies used previous literature estimates to inform
evaluations, with three being evaluations alongside
observational studies with assumed quit rates and inter-
vention costs;40 47 50 ﬁve studies were modelling-
based.44 45 49 53 54 Two observational studies found that
cessation interventions would generate greater cost
savings compared to the cost required to deliver the
intervention. Ayadi et al40 reported that an intervention
costing US$24 per person, if applied to the US popula-
tion, would generate US$ 8 million net saving in health-
care costs, a ratio of approximately 1:333 333. Thorsen
et al50 reported savings of US$137 592 for an interven-
tion costing US$15 366 given to low-income women in
the US, a ratio of approximately 1:9. One observational
study conducted by Pollack47 found that a cessation
intervention costing US$45 per person would avert 108
SIDs if given to all pregnant smokers in the US, suggest-
ing that the cessation service would cost US$210 500 per
SID averted.
Three modelling studies were also conducted in the
USA, and reported favourable cost-saving estimates.
Marks et al45 reported that taking into account the long-
term costs averted, the ratio of cost savings to interven-
tion cost was 1:3.26. Hueston et al44 estimated that cessa-
tion interventions were cost-effective if the intervention
costed US$80 or less in 1989 prices (US$152.73 in 2014
prices) and achieved a 18% quit rate, while Shipp et al49
estimated that an intervention would be cost-neutral if
the cost of delivering the intervention in 1989 prices
(2014 prices) was US$32 (US$61.09) or lower. Using the
same exchange rate US$1=GBP0.677173 (correct as of
April 2015), the values in UK 2014 prices were £103.42
and £41.37, respectively.
Using a model constructed for informing the National
Institute of Health and Care Excellence (NICE) in the
UK, Taylor53 estimated that rewards (interventions
where the participant received a ﬁnancial or non-
ﬁnancial reward for meeting certain criteria) and ‘other
interventions’ (not cognitive behavioural therapies
(CBT), ﬁnancial or pharmacological interventions) were
dominant over usual care; however, other cessation inter-
ventions had favourable incremental cost-effectiveness
ratios (a ratio of the difference in cost over the differ-
ence in effectiveness), assessed as £4005 per additional
QALY for CBT, £2253 per additional QALY for pharma-
cotherapies, £1992 per additional QALY for feedback
and £2253 per additional QALY for stages of change. In
another model constructed for NICE to inform guid-
ance on secondary care interventions, Mallender et al54
reported that even considering short-term outcomes up
to 3 years postintervention, behavioural interventions
appeared to be cost-effective with incremental cost-
effectiveness ratios of £5445 and £1331 per additional
QALY for high and low intensity, while incentives were
less cost-effective with incremental cost-effectiveness
ratios of £41 088 and £60 409 per additional QALY for
conditional and non-conditional incentives. However,
the incremental cost-effectiveness ratios decreased as the
perspective was increased to include the lifetime for the
mother and her infant, and reported that all the
interventions modelled achieved a 100% probability of
cost-effectiveness by £31 000 per additional QALY in the
lifetime analysis.
DISCUSSION
This review found 18 studies which included economic
evaluations of cessation interventions delivered during
pregnancy, however, only six of these (33%) were judged
as high quality. Seventeen studies identiﬁed within-
pregnancy interventions as being cost-effective, with only
one trial reporting that usual care was better than the
experimental intervention.48 The current evaluations
were generally well described, utilised appropriate
health outcomes and drew realistic conclusions based on
their results. Conversely, aspects where the analyses were
in deﬁcit included consideration of all major and rele-
vant fetal and maternal health outcomes, use of an
appropriate time horizon, and controlling for uncer-
tainty using statically robust methods.
A limitation of this review is that the QHES is a sub-
jective instrument. This was highlighted by the need for
discussion among reviewers to resolve occasional dis-
agreements about how some QHES items related to
studies. However, ﬁrst, the same issue applies to other
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Table 4 Studies with evaluations informed by primary data collection as grouped by quality as judged by the QHES
Study Intervention Comparator
Incremental
cost (£)
Incremental quit
rate (%)
Incremental cost per
additional quitter (£)
Incremental cost per
additional QALY (£)
Studies judged high quality on QHES (≥75)
Cooper et al32 NRT with behavioural
support
Placebo with behavioural
support
98.21* 1.8 5456.34* 2812.55*
Tappin et al34 Financial incentives with
standard NHS care†
Standard NHS care† 157.36‡ 14.0 1124.00‡ 579.38‡
Ussher 201533 Physical activity with
standard NHS care†
Standard NHS care† −35.39 1.3 DOMINANT DOMINANT
Ruger et al17 Counselling+self-help
materials
Brief advice and self-help
materials
304.04 −1.6 DOMINATED DOMINATED
Studies judged fair quality on QHES (50–74)
Ershoff et al43 Self-help materials Self-help materials 16.58 13.6 121.94 62.86
Dornelas et al41 Counselling Brief advice with
self-help materials
50.23 18.7 268.62 138.47
Ershoff et al42 Counselling Smoking cessation
programme (not defined)
149.69 11.6 1290.42 665.17
Studies judged poor quality on QHES (≤49)
Windsor et al52 Counselling+self-help
materials
Self-help materials 4.99 5.8 86.05 44.35
Windsor et al51§ Self-help materials Brief advice 7.12 4.0 178.10 91.80
Windsor et al51§ Self-help materials Brief advice 7.12 12.0 59.37 30.60
Parker et al46 Counselling No intervention 2357.40 13.4 17 592.55 9068.32
*95% CI Inc cost −£214.48 to £410.92, 95% CI ICER per quitter −£11 915.50 to £22 828.78, 95% CI ICER per QALY −£6142.01 to £11 767.41.
†Standard NHS care involves face-to-face counselling, telephone support, and up to 12 weeks of NRT.
‡95% CI Inc cost £155 to £162, 95% CI ICER per quitter £1107.14 to £1157.14, 95% CI ICER per QALY £570.69 to £596.47.
§Windsor 1988 reports two different self-help material interventions versus brief advice, and thus both interventions have been reported separately.
ICER, Incremental Cost-Effectiveness Ratio; NHS, National Health Service; NRT, nicotine replacement therapy; QALY, quality adjusted life years; QHES, Quality of Health Economic Studies.
8
Jo
n
es
M
,
et
al.
B
M
J
O
p
en
2
0
1
5
;5
:e0
0
8
9
9
8
.
d
o
i:1
0
.1
1
3
6
/b
m
jo
p
en
-2
01
5
-0
0
8
9
9
8
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 January 8, 2016 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
checklists and therefore this is likely to have been a
problem with any quality checklist utilised. Second,
there were occasions where the reviewers felt QHES
items were difﬁcult to completely address; hence reward-
ing partial achievement rather than all or none of the
available points may have been more appropriate. For
example, for QHES question three it might have been
appropriate to score in a graded fashion with points
awarded being dependent on the different types of
study design (eg, eight points for information from sys-
tematic review, seven for information from clinical trial).
This could have resulted in the points score calculated
for each study better reﬂecting the overall quality of the
methods used, potentially providing a more meaningful
comparison. Finally, despite being a good measure of
internal validity, the QHES does not measure the exter-
nal validity. Therefore, this review is unable to capture
whether the results of the included studies could be gen-
eralised to the population, consequently a meaningful
comparison across all the studies may not be possible or
appropriate. Nevertheless, the reviewers believe that the
use of QHES is appropriate to identify, across studies,
those aspects of economic evaluations which might
require development. Another consideration is that
although the review has included several unpublished
studies which we identiﬁed from published trial proto-
cols, there may be other unpublished studies which have
not been included but are relevant to the review; hence
this review may not have included all the potential
literature.
This review also has three important strengths. The
broad search strategy has allowed the review to identify
the majority of the literature published, and it is unlikely
that an evaluation has escaped being identiﬁed, while
also updating the previous review.17 Therefore, ﬁrst, this
review is the most comprehensive in this subject to date.
Second, the use of the QHES has allowed a systematic
identiﬁcation of the shortcomings in the published eva-
luations. The important impact of identifying the short-
comings of the current literature is that the review
demonstrates that the included studies have several
important omissions and analytical limitations which
future evaluations would need to remedy for more
accurate estimation of the cost-effectiveness of within-
pregnancy cessation interventions. Additionally, this is
the ﬁrst review that has conducted a qualitative synthesis
on all cessation interventions that have been evaluated
as part of clinical trials. This allows the comparison of
different within-pregnancy cessation interventions,
which is novel in this topic area, and hence permits the
decision as to which interventions appear to be the most
value for money.
We highlighted several limitations with the economic
evaluations in which we identiﬁed in the literature. Most
studies focused on a within-pregnancy time horizon, with
only four studies considering the impacts of smoking
during pregnancy on longer term outcomes.35 48 53 54
However, it is well-established that smoking is associated
with serious morbidities that can occur later in life,3 as
well as health issues for the infant during its childhood
(eg, respiratory disease).61 Therefore, to determine the
cost-effectiveness of smoking cessation during pregnancy,
the time horizon must not only capture within-pregnancy
impacts, but also impacts over the lifetime, for both
mother and infant. A further issue is that all evaluations
omit one or more of the major morbidities which are
caused by smoking in pregnancy. Most studies omitted
maternal comorbidities associated with smoking and
pregnancy, for example, placental abruption, placenta
praevia, pre-eclampsia.4 These can all lead to severe com-
plications during pregnancy, and in a worst case scenario,
death to the infant, the mother or both. However, many
studies included some adverse, smoking-related birth out-
comes and infant morbidities (eg, IBW, premature birth,
stillbirth), but rarely included more than one-condition
and did not consider any longer term impacts. Some
studies have attempted to capture the healthcare cost
savings for adverse birth outcomes avoided from cessa-
tion,40 42–45 47 50 52 but only one included the impact of
LBW and asthma on the health of the child across their
lifetime; yet this study excluded premature birth.54
Another limitation of the current literature appears to
be a general failure across studies to consider the impact
of relapse to smoking after pregnancy; only four studies
attempted to allow for this, and there was considerable
variation in relapse rates applied within these.35 48 53 54
Relapse is important since the mother’s health risks
from smoking increases with relapse, as does the infant’s
exposure to secondhand smoke.62 63 Additionally, recent
work suggests that if the mother smokes, an infant is
over twice as likely to become an adult smoker,64 poten-
tially exposing him or her to the associated lifetime
adult health risks. Hence, by not including a rate of
relapse to smoking after childbirth, most economic
models are overestimating the number of mothers who
remain abstinent after pregnancy, potentially overem-
phasising the beneﬁts of smoking cessation.
One ﬁnal consideration is the small number of studies
which robustly control for uncertainty, with only the four
most recently completed incorporating statistically robust
techniques.32 33 35 54 Controlling for uncertainty appropri-
ately is important since it can demonstrate the level of con-
ﬁdence that the decision resulting from the evaluation is
the correct one. While in the past one-way and two-way
deterministic sensitivity analyses have been considered
appropriate for gauging the impact of uncertainty, it is
now deemed better to control for all parameter uncer-
tainty through the use of probabilistic sensitivity analysis.65
By not controlling for uncertainty, decisions made on ces-
sation interventions could be incorrect, leading to a cost in
beneﬁts forgone. The present literature does not allow a
reviewer to determine how conﬁdent they are that cessa-
tion interventions are cost-effective.
Despite the limitations, included studies suggest that
cessation interventions may generally be cost-effective,
with only one study out of 18 not supporting that
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conclusion.48 From the within-trial evaluations identi-
ﬁed, there is evidence that cessation interventions involv-
ing physical activity may offer most value for money
because they are dominant (saves money and is more
effective), however, this was only based on the results of
one study, which also demonstrates that there is a degree
of uncertainty in the results.33 However, the incremental
cost per additional quitter and incremental cost per add-
itional quality adjusted life year (QALY) were relatively
low for all other interventions except motivational inter-
viewing, the largest being £17 592.55 per additional
quitter (£9068.22 per additional QALY).46 This was
further supported by the evaluations based on models
which either returned very favourable cost-offset ratios
for the US-based studies and the incremental cost per
additional QALY ratios in UK based models, with one
study suggesting that all interventions achieved a 100%
probability of cost-effectiveness at a willingness to pay of
£31 000 per QALY.54 Cessation interventions in non-
pregnant populations have often been found to be very
cost-effective,16 and this review would suggest that cessa-
tion interventions within-pregnancy continue to meet
this criteria. However, in the four studies that utilised a
probabilistic sensitivity analysis, there was evidence of
uncertainty which may warrant further investigation, and
could impact on the estimated cost-effectiveness of cessa-
tion interventions. Therefore, it would seem logical that
policymakers should continue to fund cessation inter-
ventions for pregnant women as current evidence
suggest that they offer value for money; however, there is
some uncertainty in the results of which the policymaker
might wish to be aware.
CONCLUSIONS
This review demonstrates that although smoking during
pregnancy is an important public health issue, there are
relatively few high quality economic evaluations demon-
strating the cost-effectiveness of cessation interventions,
and many of these have methodological shortcomings.
Although the majority of included studies suggested that
within-pregnancy cessation interventions appeared to be
cost-effective, the quality of evidence tended to be poor.
To become more comprehensive and to estimate cost-
effectiveness more accurately, future economic evaluations
of smoking cessation in pregnancy should investigate
uncertainty more robustly, use better estimates for the
postpartum relapse, extend beyond a within-pregnancy
time horizon and include the major morbidities for the
mother and her infant for within-pregnancy and beyond.
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